Lupin Reviews R&D Thrust, Biosimilars Plan On Course
Executive Summary
Lupin is reorienting its R&D priorities with a thrust on more definitive, near and mid-term opportunities while rationalizing its discovery program and trimming its headcount. The firm’s biosimilars program though remains on track with a filing anticipated in Europe and Japan this fiscal.
You may also be interested in...
Cutbacks Rise As Indian Pharma Tightens Control On Costs
Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.
Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.
Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.